Herceptin (Trastuzumab) News and Research

RSS

Herceptin (Trastuzumab) is a monoclonal antibody that binds to HER2 (human epidermal growth factor receptor 2), and can kill HER2-positive cancer cells. Monoclonal antibodies are made in the laboratory and can locate and bind to substances in the body, including cancer cells. Herceptin is used to treat breast cancer that is HER2-positive and has spread after treatment with other drugs. It is also used with other anticancer drugs to treat HER2-positive breast cancer after surgery. Herceptin is also being studied in the treatment of other types of cancer.

Study shows precision medicines could aid more breast cancer patients via RNA-targeting

When women or men receive the worrisome diagnosis of breast cancer, that news comes with an important piece of information, namely, whether their cancer is HER2-positive or HER2-negative.

8 Feb 2019

FDA grants approval to first biosimilar for treatment of patients with breast, stomach cancers

The U.S. Food and Drug Administration today approved Ogivri (trastuzumab-dkst) as a biosimilar to Herceptin (trastuzumab) for the treatment of patients with breast or metastatic stomach cancer (gastric or gastroesophageal junction adenocarcinoma) whose tumors overexpress the HER2 gene (HER2+).

4 Dec 2017

Delivering microRNAs in cancer treatment: an interview with Dr Conde and Prof Artzi

microRNAs (miRs) are small endogenous noncoding RNA molecules (20–23 nucleotides) derived from imperfectly paired hairpin RNA structures naturally encoded in the genome that act specifically as triggering molecules to control translational repression or mRNA degradation.

11 Mar 2016

Study shows rare HER2 missense mutations do not spread breast cancer on their own

Results of a new laboratory study by Johns Hopkins Kimmel Cancer Center researchers suggests that some rare “missense” mutations in the HER2 gene are apparently not — on their own — capable of causing breast cancer growth or spread.

12 Nov 2015

Scientists trace out intricate molecular pathway that may explain tamoxifen resistance in breast cancer patients

For reasons unknown, many patients with breast cancer treated with the estrogen receptor-blocking drug tamoxifen eventually become resistant to the treatment despite the fact that their cancer cells still have the estrogen receptor proteins that the drug normally targets.

24 Sep 2015

Scientists discover important new biomarker that could improve HER2 targeted cancer treatments

Scientists from the School of Pharmacy & Pharmaceutical Sciences, Trinity College Dublin have made a significant discovery of a new biomarker which may help overcome resistance to newer and more targeted anti-cancer drugs, such as Herceptin, for HER2 positive cancers. These findings may also help the early identification of patients who will benefit more from these treatments.

11 Jun 2014

Magnetic nanoparticle (mNP) hyperthermia in breast cancer treatment

In a presentation exploring the promise of magnetic nanoparticle (mNP) hyperthermia in breast cancer treatment, Dartmouth researcher P. Jack Hoopes, DMV, PhD, reviewed preclinical studies conducted at Norris Cotton Cancer Center and discuss plans for early-phase clinical studies in humans at the annual meeting of the American Association for Cancer Research (AACR).

8 Apr 2014

FDA grants accelerated approval of Perjeta for people with HER2-positive early stage breast cancer

The U.S. Food and Drug Administration granted accelerated approval of a Perjeta- (pertuzumab) regimen for neoadjuvant treatment (use before surgery) in people with high-risk, HER2-positive early stage breast cancer.

2 Oct 2013

Combination of cell-killing radioactive particle and antibody is safe for treating cancers

An experimental treatment that combines a cell-killing radioactive particle with an antibody that homes in on cancer cells is safe in the treatment of cancers spreading through patients' abdomens, according to data from a first-in-human study presented today at the Society of Nuclear Medicine and Molecular Imaging annual meeting in Vancouver.

11 Jun 2013

Subcutaneous administration of Herceptin preferred by HER2-positive breast cancer patients over IV

Results from the PrefHer (Patient Preference for Subcutaneous (SC) versus Intravenous (IV) Herceptin) trial show that 92% of early HER2-positive breast cancer patients favoured quicker SC administration of Herceptin compared to the standard IV infusion.1 Presented at the St. Gallen Breast Cancer Conference in Switzerland.

15 Mar 2013

Renowned biotech researcher to receive TJU's Lennox K. Black International Prize

Thomas Jefferson University will honor the renowned biotech researcher whose discoveries led to a slew of innovative drugs that revolutionized treatment including Herceptin-one of the first gene-based medications for breast cancer-with its prestigious Lennox K. Black International Prize for Excellence in Biomedical Research.

27 Nov 2012

Obesity and breast cancer recurrence: an interview with Dr. Joseph Sparano

Breast cancer recurrence is a major problem after treatment of localized breast cancer. The risk of recurrence depends on several factors including the stage of presentation and the biology of the disease.

3 Sep 2012

Herceptin® (trastuzumab) delivery methods: an interview with Dr Gustavo Ismael

Approximately 20% of all breast cancer patients have overexpression of HER2 (human epidermal growth factor receptor 2), resulting in a more aggressive phenotype, and a poor prognosis.

28 Aug 2012

Herceptin® could potentially be delivered via a standard injection

A new method of delivering a commonly used breast cancer drug could result in considerably less time spent in hospital for some women undergoing breast cancer treatment, according to the results of a Phase 3 trial published Online First in The Lancet Oncology.

9 Aug 2012

Panel of HuCAL Anti-Drug Antibodies to be launched by AbD Serotec

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that its division for research and diagnostic antibodies, AbD Serotec, will launch a series of novel anti-drug antibodies (ADAs) to strengthen its position as a leading provider of diagnostic reagents.

23 May 2012

Halozyme first quarter net loss increases to $15.1 million

Halozyme Therapeutics, Inc. today reported financial results for the quarter ended March 31, 2012.

8 May 2012

Leica receives FDA Pre-Market Approval for new HER2 IHC test

Leica Biosystems, a division of Leica Microsystems, announced that it has received Pre-Market Approval from the U.S. Food and Drug Administration for the Leica Bond Oracle HER2 IHC System with the Leica BOND-MAX, establishing their commitment to developing quality companion diagnostic products.

26 Apr 2012